[go: up one dir, main page]

WO2004032855A2 - Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 - Google Patents

Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 Download PDF

Info

Publication number
WO2004032855A2
WO2004032855A2 PCT/US2003/031778 US0331778W WO2004032855A2 WO 2004032855 A2 WO2004032855 A2 WO 2004032855A2 US 0331778 W US0331778 W US 0331778W WO 2004032855 A2 WO2004032855 A2 WO 2004032855A2
Authority
WO
WIPO (PCT)
Prior art keywords
beta
growth factor
transforming growth
angiogenesis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/031778
Other languages
English (en)
Other versions
WO2004032855A3 (fr
Inventor
Eric G. Marcusson
Nicholas M. Dean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Priority to AU2003275474A priority Critical patent/AU2003275474A1/en
Publication of WO2004032855A2 publication Critical patent/WO2004032855A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004032855A3 publication Critical patent/WO2004032855A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Definitions

  • transforming growth factor-beta 3 upregulation of transforming growth factor-beta 3 expression has been demonstrated in hepatocellular carcinoma cells and perineoplastic stroma of the liver, suggesting a role in tumor progression (Abou-Shady et al . , Am. J. Surg . , 1999, 177, 209- 215) . Furthermore, increased expression of transforming growth factor-beta 3 in breast cancer patients is a prognostic indicator inversely correlated with survival (Ghellal et al . , Anticancer Res . , 2000, 20 , 4413-4418).
  • Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
  • the suspension may also contain stabilizers.
  • Pharmaceutical compositions include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations.
  • the pharmaceutical compositions and formulations used may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes d'inhibition de l'angiogénèse faisant appel à des inhibiteurs du facteur de croissance transformateur bêta 3. Ces méthodes permettent de prévenir, de réduire ou de traiter l'angiogénèse. L'invention concerne des méthodes de traitement de maladies et de troubles associés à l'angiogénèse, et d'états associés à une croissance de vaisseaux sanguins aberrante ou excessive. L'invention concerne des inhibiteurs du facteur de croissance transformateur bêta 3 comprenant des petites molécules, des anticorps, des peptides (notamment des peptides négatifs dominants) et des composés antisens, notamment des ribozymes, des molécules d'ARN inhibitrices, notamment des molécules d'ARNsi et des oligonucléotides antisens.
PCT/US2003/031778 2002-10-07 2003-10-07 Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 Ceased WO2004032855A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003275474A AU2003275474A1 (en) 2002-10-07 2003-10-07 Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41707402P 2002-10-07 2002-10-07
US60/417,074 2002-10-07

Publications (2)

Publication Number Publication Date
WO2004032855A2 true WO2004032855A2 (fr) 2004-04-22
WO2004032855A3 WO2004032855A3 (fr) 2005-06-02

Family

ID=32093960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031778 Ceased WO2004032855A2 (fr) 2002-10-07 2003-10-07 Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3

Country Status (2)

Country Link
AU (1) AU2003275474A1 (fr)
WO (1) WO2004032855A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109548A3 (fr) * 2007-03-02 2009-02-26 Mdrna Inc Composés d'acides nucléiques conçus pour inhiber l'expression du gène tgfb et utilisations de ceux-ci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109548A3 (fr) * 2007-03-02 2009-02-26 Mdrna Inc Composés d'acides nucléiques conçus pour inhiber l'expression du gène tgfb et utilisations de ceux-ci

Also Published As

Publication number Publication date
AU2003275474A8 (en) 2004-05-04
AU2003275474A1 (en) 2004-05-04
WO2004032855A3 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
CN110234326B (zh) 用于抑制因子xii基因表达的组合物和方法
JP4762889B2 (ja) 血管形成及び腫瘍成長を阻止するための核酸化合物
AU2002344237B8 (en) Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions
KR101749352B1 (ko) Ｓｉｒｔ1에 대한 천연 안티센스 전사체의 억제에 의해 ｓｉｒｔ1 관련된 질환의 치료
US8410067B2 (en) Inhibition of versican with siRNA and other molecules
US20090270487A1 (en) Compositions and methods for inhibiting the synthesis or expression of MMP-1
US8198259B2 (en) Treatment of neurological disorders by dsRNA administration
KR20090042297A (ko) ＩＯＰ―관련 증상을 치료하기 위한 그렘린의 ＲＮＡｉ 매개 억제
KR20080091108A (ko) 안구의 혈관신생 치료용 ＨＩＦ１Ａ의 ＲＮＡⅰ－매개 억제
AU673537B2 (en) Antisense polynucleotides
EP2520651A2 (fr) Arnsi permettant d'inhiber l'expression de c-met, et composition anticancéreuse le renfermant
CA2860676A1 (fr) Compositions organiques pour traiter des maladies associees a la beta-catenine
EP1716235B1 (fr) Inhibiteurs de la signalisation cellulaire liée au tgf-beta/tgf-r pour le traitement des maladies neurodégénératives
US20060122136A1 (en) Effective and stable DNA enzymes
WO2004032880A2 (fr) Methode permettant d'inhiber l'angiogenese a l'aide d'inhibiteurs ship-1
EP1325955A1 (fr) Composés et méthodes pour l'identification et/ou la validation d'une cible
EP3452593B1 (fr) Lncrna meg3 pour la thérapie et le diagnostic du remodelage cardiaque
WO2004032855A2 (fr) Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3
CN116096420A (zh) 利用miR-33b抑制物质的动脉瘤的预防或治疗
US20060258610A1 (en) Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
KR20200123165A (ko) 돌연변이체 p53-특이적 siRNA를 이용하는 암 치료적 표적화
EP2978847B1 (fr) Ribozymes en tête de marteau ciblant mir-21
WO2008109468A1 (fr) Composés d'acide nucléique pour inhiber l'expression du gène mmp et utilisations de ceux-ci
JP2009510174A (ja) ブデソニドおよびｉｌ−４受容体アルファを標的化するアンチセンスオリゴヌクレオチドを用いた併用療法
KR20140021594A (ko) 혈관 장벽 기능이 변경된 장애의 치료

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP